LMG
0.016
60%
OVT
0.001
-50%
PNT
0.007
40%
IBR
0.024
-46.7%
AUR
0.019
26.7%
CGR
0.045
-39.2%
CVB
0.025
25%
BRY
0.013
-31.6%
SRJ
0.005
25%
RPM
0.012
-20%
CYB
0.051
21.4%
A8G
0.165
-17.5%
PL9
0.006
20%
H3E
0.005
-16.7%
SLB
0.305
19.6%
GLB
2.6
-16.1%
PLC
0.007
16.7%
MHC
0.021
-16%
EQR
0.445
15.6%
AVW
0.006
-14.3%
AR9
0.064
14.3%
AX8
0.006
-14.3%
DM1
0.008
14.3%
NS1
0.006
-14.3%
IVZ
0.072
14.3%
VRS
0.04
-13%
DEL
0.1
13.6%
IVG
0.035
-12.5%
OD6
0.125
13.6%
PCL
0.007
-12.5%
EMD
0.053
12.8%
PSL
0.035
-12.5%
OR3
0.08
12.7%
AAU
0.008
-11.1%
GTE
0.009
12.5%
QEM
0.016
-11.1%
GWR
0.15
11.1%
RAD
0.008
-11.1%
VKA
0.01
11.1%
DUN
0.041
-10.9%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Control Bionics (ASX:CBL): Expands global reach with exclusive UK and Ireland distribution agreement

Control Bionics (ASX:CBL) expands global reach with exclusive UK and Ireland distribution agreement.

• Exclusive distribution of NeuroNode® by Smart Box in the UK and Ireland.
• Access to Smart Box’s established network of healthcare professionals and end-users.
• Strengthening Control Bionics’ presence in the European market.

Jeremy Steele, CEO of Control Bionics, commented: “The NeuroNode® has already been paired with hundreds of Smart Box
devices and devices with Smart Box software around the world.”

Read the ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240909/pdf/067np1hzgg2sbv.pdf